Hoth Therapeutics, Inc. (HOTH), a clinical-stage biopharmaceutical company, announced on Thursday that it has obtained Japan Country Patent No. 7677628 for its HT-KIT platform.
The patent was granted by the Japan Patent Office on May 7, 2025, providing exclusive protection through August 27, 2039.
The patent covers Hoth's novel approach using splice-switching oligonucleotides or SSOs to selectively disrupt KIT gene expression in mast cells, which are involved in conditions ranging from chronic hives to rare cancers.
This patent ensures long-term commercial exclusivity in the Japanese pharmaceutical market.
Robb Knie, CEO of Hoth Therapeutics, said, "Securing intellectual property protection in Japan—a globally significant pharmaceutical market—underscores the global value of HT-KIT. We see strategic licensing potential across Asia as we move this asset forward."
Hoth continues to seek strategic global partners, especially in Asia, to co-develop and commercialize HT-KIT and other innovative therapeutic platforms.
Currently, HOTH is trading at $1.40, up by 6.44 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.